From the Coordinating Center for Clinical Trials, Office of the Director, National Cancer Institute, National Institutes of Health, Bethesda.
Information Technology Manager, Essex Management, LLC, Rockville.
Cancer J. 2022;28(2):111-117. doi: 10.1097/PPO.0000000000000578.
The COVID-19 pandemic posed unprecedented strain on enrollment to cancer clinical trials and their conduct. Here, we highlight an analysis using information from the National Cancer Institute (NCI) Clinical Trials Reporting Program database to describe enrollment patterns to interventional cancer treatment trials at NCI-Designated Cancer Centers during the pandemic. Enrollment to cancer treatment trials at NCI-Designated Cancer Centers decreased precipitously early in the pandemic and has not yet fully returned to the 2019 baseline as of mid-2021. We discuss possible reasons for this and how some of the changes in clinical trial conduct implemented during the pandemic may become part of the standard conduct of NCI-supported clinical trials and broaden access to trials.
COVID-19 大流行给癌症临床试验及其开展带来了前所未有的压力。在这里，我们利用美国国家癌症研究所（NCI）临床试验报告计划数据库中的信息进行了分析，以描述大流行期间 NCI 指定癌症中心中干预性癌症治疗试验的入组模式。自疫情开始以来，NCI 指定癌症中心癌症治疗试验的入组人数急剧下降，截至 2021 年年中，尚未完全恢复到 2019 年的基线水平。我们讨论了出现这种情况的可能原因，以及大流行期间实施的一些临床试验管理方面的变化如何成为 NCI 支持的临床试验标准管理的一部分，并扩大试验的可及性。
